# A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

> **NCT05210582** · PHASE2 · UNKNOWN · sponsor: **Clinuvel, Inc.** · enrollment: 6 (estimated)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Afamelanotide

## Key facts

- **NCT ID:** NCT05210582
- **Lead sponsor:** Clinuvel, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-11
- **Primary completion:** 2023-04
- **Final completion:** 2023-08
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05210582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05210582, "A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05210582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*